Collegium Pharmaceutical financials
$22.23−1.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $199.9M | $193.5M | $205.4M | $209.4M | $188.0M | $177.8M | $181.9M | $159.3M | $145.3M | $144.9M | $149.7M | $136.7M |
| Gross profit | $173.2M | $172.7M | $128.4M | $129.2M | $163.9M | $152.8M | $98.3M | $96.8M | $90.8M | $91.5M | $94.6M | $80.3M |
| Gross margin | 86.7% | 89.3% | 62.5% | 61.7% | 87.2% | 86.0% | 54.0% | 60.8% | 62.5% | 63.1% | 63.2% | 58.7% |
| Operating income | $3.7M | $30.9M | $61.9M | $62.1M | $35.1M | $20.9M | $38.1M | $34.8M | $47.5M | $49.5M | $61.7M | $45.0M |
| Net income | -$15.1M | $14.5M | $17.0M | $31.5M | $12.0M | $2.4M | $12.5M | $9.3M | $19.6M | $27.7M | $31.9M | $20.6M |
| Net margin | −7.5% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% | 13.5% | 19.1% | 21.3% | 15.1% |
| Diluted EPS | $-0.46 | $0.40 | $0.36 | $0.84 | $0.34 | $0.07 | $0.32 | $0.27 | $0.52 | $0.71 | $0.82 | $0.53 |
| EBITDA | $68.5M | $86.8M | $118.3M | $118.6M | $91.7M | $77.5M | $94.6M | $76.6M | $82.9M | $84.9M | $61.7M | $45.0M |
| Operating cash flow | $71.3M | $57.1M | $123.0M | $78.4M | $72.4M | $55.4M | $84.6M | -$9.0M | $67.4M | $61.9M | $73.3M | $74.0M |
| Free cash flow | $70.8M | $56.8M | $122.4M | $78.3M | $72.4M | $54.6M | $84.1M | -$9.2M | $67.1M | $61.4M | $73.2M | $74.0M |
| Diluted shares | 32.5M | 40.1M | 47.5M | 39.4M | 39.1M | 32.8M | 39.7M | 40.2M | 40.4M | 41.4M | 47.9M | 42.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $129.5M | $268.6M | $231.3M | $150.1M | $117.3M | $96.2M |
| Short-term investments | $0.00 | $153.1M | $155.4M | $135.8M | $104.8M | $101.6M |
| Total debt | $1.09B | $802.8M | $809.3M | $808.1M | $822.9M | $837.7M |
| Total assets | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B |
| Total liabilities | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B |
| Shareholders' equity | $311.9M | $312.4M | $301.7M | $274.8M | $232.2M | $234.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology